The aim of the present study was to prepare PharmagumTM based chlorpheniramine maleate chewable tablets for the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever. Chewable tablets containing CPM was prepared by a direct compression technology. The indigenously fabricated and standardized flat faced toolings used for the preparation of chewing gum formulations. The effect of varying the concentration PharmagumTM as a gum base on release of chlorpheniramine maleate (CPM) from chewable tablets was investigated. Differential scanning calorimetry and X-ray powder diffraction spectroscopy were used for physicochemical characterization. The drug content was estimated by UV spectrophotometer at 261 nm. In vitro drug release studies of chewing gum formulations were performed in artificial saliva pH 6.8 at 37�±1oC.
Loading....